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Trafficking through a variety of cellular structures and 
organelles is essential for the interaction between gene-
delivery vectors (i.e., adeno-associated virus (AAV) and 
liposomes) and host cells/tissues. Here, we present a 
method of computer-assisted quantitative 3D biodistri-
bution microscopy that samples the whole population 
of fluorescently-labeled vectors and document their 
 trafficking routes. Using AAV as a working model, we 
first experimentally defined numerical parameters for 
the  singularity of Cy5-labeled particles by  combining 
 confocal microscopy and atomic force microscopy 
(AFM). We then developed a robust approach that 
integrates  single-particle fluorescence imaging with 3D 
deconvolution and isosurface rendering to quantitate 
viral  distribution and trafficking in human cells as well as 
animal tissues at the single-particle level. Using this quan-
titative method, we uncovered an as yet  uncharacterized 
rate-limiting step during viral cell entry, while delineating 
nuclear accumulation of virions during the first 8 hours 
postinfection. Further, our studies revealed for the first 
time that following intramuscular injection, AAV spread 
progressively across muscle tissues through endomysium 
between myofibers instead of traversing through target 
cells. Such 3D resolution and quantitative dissection of 
vector–host interactions at the subcellular level should 
significantly improve our ability to resolve trafficking 
mechanisms of gene-delivery particles and facilitate the 
development of enhanced viral vectors.
Received 3 July 2011; accepted 18 October 2011; published online  
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IntroductIon
Therapeutic gene delivery is becoming one of the major strategies 
to improve human health. For example, both viral and nonviral 
vectors (e.g., adenovirus, adeno-associated virus (AAV), liposomes, 
and nanospheres) have recently been adapted to deliver therapeu-
tic agents in an endeavor to treat human disorders.1,2 Encapsulation 
of the intracellularly-acting materials (i.e., nucleotides, proteins) 
into specialized delivery vehicles (i.e., viral capsids, nanospheres) 
that can deliver these agents to specific organelle in a controlled 
fashion is critical to attain efficient and selective pharmacological 
effects.3 To achieve such functions, these vectors have to partially 
or fully transverse a biological maze, which is mainly a multi-step 
trafficking process from cell surface binding to nuclear entry.4,5 
Consequently, development of therapeutic delivery vectors has 
concentrated on pharmacological reagents and vector variants 
that affect these pathways.6–9 Effective achievement of such efforts 
requires quantitatively evaluating the biological effect(s) of those 
reagents or vector variants on these complex trafficking routes and 
biodistribution of delivery vehicles.
During the past decades, several sophisticated fluorescence 
microscopy techniques including confocal and total internal 
reflection fluorescence (TIRF) microscopy have revolutionized 
our knowledge of specific viral trafficking events in cultured 
cells.10,11 For example, confocal microscopy with the assistance of 
2D  colocalization assay helped to suggest that AAV2 differentially 
traffic through late and recycling endosomes in a  dose-dependent 
manner,10 while TIRF microscopy–assisted live cell imaging 
helped to show that actin disruption drugs could block the retro-
grade flow of human papillomavirus on cell surface.11
However, despite advances of 2D imaging and analysis,12–14 
to date there is no method available to quantify the number and 
biodistribution of nanoscaled viral particles in animal cells and 
tissues, which is essential in evaluating the effects of pharmaco-
logical reagents and viral vector variants on nanoparticle  delivery. 
For example, many viral vectors have high particle-to-plaque 
forming unit (pfu) ratios, requiring hundreds to thousands of viri-
ons to successfully infect a single cell. This strongly suggests that 
(i) virions may take several different pathways during  infection, 
(ii) most viral entry and trafficking events might be futile,4,15 
and (iii) a significant number of the particles are defective or 
not assembled properly.16 Before one can distinguish productive 
events from nonproductive ones, it is essential to sample the entire 
population of intracellular viral particles without bias. Analysis 
of 2D images, utilized by current microscopy approaches, is not 
unbiased because it only samples one focal plane of viral particles 
within infected cells. In addition, each labeled particle is displayed 
as a discrete and intact multi-voxel fluorescent spot, and the dis-
tribution of particles in cells varies on each focal plane along the 
z-axis. 2D image from any focal plane selected for quantification is 
arbitrary; therefore, classical pixel-by-pixel colocalization analysis 
is not suitable to examine intracellular distribution of viral par-
ticles that actually exist in 3D. Finally, current centroid-counting 
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method fails to quantitate viral particles in cells because of the fact 
that particles may aggregate or move into a subresolutional region 
like vesicles to give a single fluorescent spot, as is common for 
nanoparticle trafficking. As a result, no method to date is available 
for quantitatively determining the biodistribution of nanoscaled 
vectors in three dimensions (such as outside or inside nucleus, or 
traversing nuclear membrane).
Here, based on recent advances with computational image 
processing,17,18 we developed a sensitive and reliable methodology 
by integrating single-particle imaging and 3D quantification into 
classical immunofluorescence to quantitate the trafficking kinet-
ics and biodistribution of nanoparticles in 3D animal cells and 
tissues. Using Cy5-labeled AAV as a working model, we quantita-
tively investigated the nuclear entry kinetics and biodistribution of 
AAV2 in human cells and mouse tissues. This study demonstrates 
the potential of this methodology in screening pharmacological 
reagents and vector variants for the development of therapeutic-
material delivery strategies as well as in understanding the intrac-
ellular behavior of delivery viral vectors in vitro and in vivo.
results
Quantitative 3d distribution microscopy
To precisely track and localize labeled particles in cells and tis-
sues, we developed an object-based quantitative 3D distribution 
microscopy which is composed of two steps: (i) assess the local-
ization of particles and (ii) quantitate the number of particles 
in each cellular structure. Here, we used localization of particles 
in nucleus as an example to explain this method. As diagramed in 
Figure 1a-A, five nanoparticles (P1–P5 in four groups G1–G4) 
are differentially localized in a cell, with P1 inside the nucleus, 
P2 transversing nuclear membrane, P3–P5 outside of the nucleus, 
and specially P4 and P5 associated with a subresolutional region 
(i.e., vesicles with diameter less than 200 nm). Confocal micro-
scope is used to create a z-stack sectioning through the entire 
cell and generate 3D fluorescence images. Image distortions 
are a natural aspect of an optical microscope (noise, scatter, 
glare, and blur) and diminish the contrast and resolution of raw 
images, thus impairing the accuracy of quantitative image analy-
sis. To counteract these problems, restorative 3D deconvolution 
is used to reverse the optical distortions, negating the effects of 
the  optical system that are represented by its point spread func-
tion (PSF, Supplementary Figure S1a). After 3D deconvolution, 
the fluorescence images are visualized by 3D volume rendering as 
shown in Figure 1a-B, with four fluorescence spots (1–4) formed 
by corresponding particles.
To determine the localization of each particle in an object-by-
object manner, we first employ isosurface rendering by threshold-
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Figure 1 object-based quantitative 3d distribution microscopy. (a) Working model for object-based 3D biodistribution measurement is shown 
in X/Z dimensions. (A) Actual localization of labeled particles and nucleus, with five particles localized in four optically resolvable groups (G1–G4), 
(B) expected fluorescence signal (spots 1–4) from four groups of labeled particles by 3D confocal microscopy, and (C) four volume of interest (V1–V4) 
defined by the fluorescence spots in (B) with the assistance of isosurface rendering. (b) Distribution of Cy5-AAV2 particles in HeLa cells at 6 hours 
postinfection. Upper panel is the fluorescence signal from 3D confocal microscopy, with red Cy5-AAV2 and blue 4’,6′-diamidino-2-phenylindole–stained 
nucleus. Bar = 6 μm. Lower panel is the isosurface rendering and shows the different localization of viral particles: red is in cytoplasm, cyan is traversing 
nuclear membrane, and yellow is inside of nucleus. (c) Example of 3D deconvolution of fluorescence signal of Cy5-AAV2 particles. This improves the 
signal-to-noise ratio and dimensional resolution of fluorescence signal from a single Cy5-AAV2. 3D surface plots (right panel) of the fluorescence signal 
from a single particle before and after deconvolution were generated by ImageJ. Pixel size in X and Y is 0.13 × 0.13 μm. AAV, adeno-associated virus.
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(Supplementary Figure S1a, dashed blue line). With this method, 
we create a volume of interest (VOI) for each fluorescence spot from 
an optically resolvable particle group (Figure 1a-A: G1–G4; and 
Supplementary Video S1: isosurface rendering). The localization 
of each particle is then determined by the amount of 4′,6′- diami-
dino-2-phenylindole (DAPI) signal within its VOI (Figure 1a-C: 
V1–V4). Specifically, the mean fluorescence intensity (MFI) of 
DAPI in V1 is the same as that in nucleus, demonstrating that P1 
is inside the nucleus; the MFI of DAPI in V3 and V4 is the same as 
that in the cytoplasm, but much lower than that in nucleus, demon-
strating that P3–P5 are outside the nucleus; and the MFI of DAPI 
in V2 is between those in nucleus and in cytoplasm, demonstrating 
that P2 is traversing the nuclear membrane.
To count the number of particles, classical centroid-counting 
method fails when several particles associate with a subresolu-
tional region and display as a single fluorescent spot (Figure 1a-B: 
spot #4), which is very common in nanoparticle trafficking. In 
addition, the amount of dyes (or dye-labeled particles) should 
be calculated by the number of emitted photon or fluorescence 
intensity instead of fluorescence volume,12,19 as there is no linear 
correlation between the amount of dyes and fluorescence volume 
(Supplementary Figure S2).20 To quantitate particles including 
those within subresolutional regions, we calculate such number 
using the total fluorescence intensity (TFI) of each fluorescence 
spot by the following formula: number of particles in structure-X 
= ∑TFIstrX/mTFIs, in which TFIstrX denotes the TFI of fluorescence 
spots formed by labeled particles in cellular structure X and 
mTFIs denotes the mean value of TFI experimentally calculated 
from fluorescence spots formed by a single particle. Using quan-
titatively-labeled fluorescence beads (InSpect Image Intensity 
Calibration beads from Invitrogen), we demonstrated that TFI but 
not volume linearly correlated with the amount of dyes on beads 
(Supplementary Figure S2a) and the number of dye-labeled 
objects can be precisely calculated from TFI (Supplementary 
Figure S2b), which validated the accuracy of this intensity-based 
quantification. In addition, compared with earlier studies,12,19 this 
object-by-object quantification method only calculates the signal 
from viral particles but not the automatically system-generated 
noise signal prevalent in the digital images because these noise 
are usually bright fluorescence spots with only one or two pixels/
voxels that are filtered away from the particle-formed fluorescence 
spots with 10 or more voxels (Figures 1b,2c,3a). Such feature 
 further improves the precision of this method.
AAV particle labeling, localization, and quantification
With this method, one is able to quantitate the biodistribution of 
nanoscaled particles in cells/tissues by specifying the number and 
localization of particles in each cellular structure. In the following 
context, we quantitate the distribution of Cy5-AAV2 particles in 
HeLa cells at 6 hours postinfection (p.i.) to fully demonstrate this 
method.
Labeling viruses with fluorochromes has been extensively 
used in imaging particle trafficking.11 We chemically conjugated 
the effect of viral particles with Cy5 to minimize autofluores-
cence in cells and tissues. Electron microscopy data demonstrated 
that the  physical morphology of AAV2 was not affected by Cy5 
 conjugation and most of the labeled virions remained as single 
particles (Supplementary Figure S3a). Labeling did not impact 
transduction efficiency significantly as indicated by green fluores-
cence protein (GFP) reporter gene assay (Supplementary Figure 
S3b,c). SDS-PAGE and fluorography of Cy5-AAV2 demonstrated 
that fluorochromes were specifically coupled to all three capsid 
proteins (VP1,2,3) as indicated by three fluorescence bands 
(Supplementary Figure S3d). This specificity of labeling was 
validated in human cells using mouse monoclonal antibody A20 
which only recognizes the intact AAV2 particles (Supplementary 
Figure S3e). These results demonstrated that both morphology 
and functionality (A20 binding and infectivity) of these labeled 
virions are the same as unlabeled ones.
At 6 hours p.i. with Cy5-AAV2 at 5,000 vector genomes per 
cell (vg/cell), HeLa cells were fixed and their nuclei were stained 
with DAPI. A Zeiss710 confocal fluorescence microscope was 
used to create a z-stack sectioning through the entire cell for each 
fluorochrome at the optimal z-step (well-characterized Nyquist 
sampling frequency). We employed AutoDeblur software (Media 
Cybernetics) for the deconvolution using an iterative constrained 
blind algorithm to remove out-of-focus haze, blur, and noise. After 
3D deconvolution, the fluorescence signal from AAV particles was 
visualized by 3D volume rendering (Figure 1b). Consistent with 
theoretical confocal PSF,20 the fluorescence signal from a labeled 
particle is shaped as prolate-spheroid in 3D, with an approximate 
equatorial radius a = 0.2–0.3 μm and polar radius b = 0.3–0.4 μm, 
which resulted in the volume range of less than 0.13 μm3. These 
signals with prolate-spheroid-shape had improved signal-to-
noise ratio up to three- to fourfold (Figure 1c). Resolution was 
also enhanced in all three dimensions evaluated by full width at 
half maximum (0.15–0.2 μm in X/Y and 0.3 μm in Z compared 
with standard confocal resolution limit of 0.3–0.4 μm in X/Y 
and 0.6 μm in Z, Figure 1c, Supplementary Figure S1). We then 
employed isosurface rendering module in IMARIS software 
(Bitplane, Zurich, Switzerland) to generate VOIs for the signals 
from each optically resolvable  Cy5-AAV2 group and thereafter 
determined the localization of Cy5-AAV2 particles to nucleus by 
DAPI signal. As shown in lower panel of Figure 1b, red spots rep-
resent the particles outside of nucleus, cyan spots represent the 
particles associated with nuclear membrane, and yellow spots rep-
resent the particles inside of nucleus. ∑TFIstrX was then calculated 
by the TFIstrX for each  fluorescence spot. To quantitate the particles 
in each type of localization, we derived the value of mTFIs in the 
following studies.
We characterized the fluorescent signal of a single Cy5-AAV2 
particle by three parameters (volume, MFI, and TFI). 4–6 × 107 
Cy5-AAV2 particles were loaded onto grid coverslips to yield a dis-
tribution of ~1 particle per 5 μm2. Uniformly labeled particles were 
obtained as indicated by confocal microscopy of Cy5-AAV2 on 
the coverslip (Figure 2a, left). Profiles of fluorescence  signal inten-
sity for two representative Cy5-AAV2 particles follow Gaussian 
distribution (Figure 2a, right), suggesting that fluorescence signal 
was from single particles.11 The fluorescence signal (thresholded as 
dashed blue line in Supplementary Figure S1a) from Cy5-AAV2 
had a diameter of 0.5–0.6 μm, comparable to the fluorescence 
signal generated by other nanoscaled viruses (e.g., SV40).11 3–5 
regions from each coverslip were imaged using the microscope 
settings for quantitative analysis (see Materials and Methods), and 
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2–3 Z-stack images were taken for each region. The distribution 
of Cy5-AAV2 on the same regions was verified using atomic force 
microscopy. Only the regions on which the minimum distance 
between every two physically dissociated  Cy5-AAV2 particles was 
larger than 0.5 μm (Figure 2b) were  chosen for later quantifica-
tion. Thus, we demonstrated that each fluorescence spot visual-
ized by fluorescence microscopy represented a single Cy5-AAV2 
particle. Images from these chosen regions were processed with 
3D deconvolution, reconstruction, and isosurface rendering 
(Figure 2c). Three statistics (volume, Cy5 MFI, and Cy5 TFI) of 
each isosurface-coated fluorescence spot were used to define the 
singularity of labeled particles. Volume was plotted for all fluores-
cent objects (Figure 2d-A) and could fit to a Gaussian curve indi-
cating a normal distribution. According to theoretical confocal 
PSF,20 we defined Cy5-AAV2 objects with volume smaller than 
0.13 μm3 as the 3D fluorescence pattern for a single Cy5-AAV2. 
These defined single Cy5-AAV2 objects had a mean value of Cy5 
TFIs at 44834 ± 16447.3 arbitrary units (a.u.) (Figure 2d-B) and 
a mean value of Cy5 MFI at 2438 ± 310.6 a.u. (Supplementary 
Figure S5a).
The complexity of the cellular environment may affect the 
fluorescent properties from a single Cy5-AAV2. We analyzed 
whether single Cy5-AAV2 particles on glass had similar fluores-
cent properties on cells. Briefly, we incubated 5,000 Cy5-AAV2 
per HeLa cells (over a surface area of ~2,000 μm2) at 4 °C for 40 
minutes to allow a dispersed distribution of Cy5-AAV2 particles 
over the cell surface (Figure 3a). Specificity of viral fluorescence 







































































































































Figure 2 characterization of fluorescence signal for single cy5-AAV2 particles. (a) Representative confocal image (left) of Cy5-AAV2 bound to 
coverslip. Bar = 2 μm. Representative fluorescence intensity profiles (right 1–2) of two Cy5-AAV2 particles (indicated at left). (b) Atomic force micros-
copy image of Cy5-AAV2 particles (arrowheads) from the same glass coverslip as in a demonstrated the dispersity of viral particles on the coverslip. 
(c) 3D reconstruction of deconvolved confocal images (left: Cy5-AAV2 in red) and subsequent 3D isosurface rendering images (right: Cy5-AAV2 
in yellow). Bar = 5 μm. (d) Histograms of volume (A) and total fluorescence intensity (B) for all Cy5-AAV2 particles recorded from the coverslip in 
a and b. The mean values of total fluorescence intensity was 44834 ± 16447.3 a.u. AAV, adeno-associated virus.
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cells (Supplementary Figure S4). We then collected the imag-
ing data and analyzed the three parameters (volume, MFI, and 
TFI) exactly as described above for in vitro characterization. The 
distribution of volumes was almost identical to the results from 
the analysis on coverslip (Figures 2d-A,3b-A). The same range 
of volumes (≤0.13 μm3) was used to define the fluorescence sig-
nal from single Cy5-AAV2 in cells. In the cellular environment, 
single Cy5-AAV2 objects have a mean value of Cy5 TFIs at 47568 
± 13345.5 a.u. (Figure 3b-B) and Cy5 MFI at 2516 ± 256.5 a.u. 
(Supplementary Figure S5b), which is not significantly different 
from the values determined on coverslip. Consistency between 
the fluorescent signal from coverslip and cell culture supports 
that our characterization and quantification by this method 
is reliable. With these calculated mTFIs (=47568 a.u.), we then 
determined the number of Cy5-AAV for each location at 6 
hours p.i.: 150 in the whole cell, 37 in nucleus, 6 associated with 
nuclear membrane, and 107 localized in cytoplasm (Figure 1b, 
Supplementary Video S2).
With this scenario, the subset of Cy5-AAV2 fluorescence spots 
with specific nuclear localization can be quantitated by DAPI 
fluorescence signal within each viral VOI and calculated mTFIs 
(Supplementary Video S2). By applying isosurface render-
ing to the nuclear DAPI  signal, the relative localization between 
AAV2 particles and nucleus can be easily and unambiguously 
visualized (Supplementary Video S2). Compared with previous 
studies,12,13,19 this method not only allows one to assess the viral 
distribution from the view of entire population but also allows 
one to locate each individual particle into finer subcellular struc-
tures (i.e., inside/outside nucleus or traversing nucleus, as shown 
in Figure 1b). By  determining the fluorescence parameters for 
single particles, this method, for the first time, also allows one to 
quantitate the number of virions in various cellular structures. 
For example, including nuclear targeting,  colocalization of AAV2 
with other  specific cellular structures (e.g., AAV-cell  membrane, 
 AAV-lysosome) and corresponding trafficking kinetics were 
quantitatively investigated using this method.
Kinetics of AAV2 trafficking in endo/lyso vesicles and 
nucleus
Intracellular trafficking in small vesicles like endosomes and 
 lysosomes is essential for productive viral infection. For example, 
AAV2 has been shown to undergo successive endosomal traf-
ficking and sorting after viral entry.10 We tested the applicabil-
ity of this method toward elucidating these essential events using 
lysosomal association of AAV2 as an example. HeLa cells were 
incubated with Cy5-AAV2 (5,000 vg/cell) at 4 °C for 40 minutes. 
After removing unbound virions, cells were incubated at 37 °C 
and harvested at 0 hour, 2 hours, 4 hours, 8 hours, and 13 hours 
p.i. and fixed with paraformaldehyde. Lysosomes were labeled 
with monoclonal Lamp1 antibody. Z-stack images were cap-
tured through the entire cell using a Zeiss LSM710 laser scanning 
confocal microscope. After 3D deconvolution and reconstruc-
tion of image stacks, we measured the association between lyso-
somes and AAV2 particles over time. Our results demonstrated 
that about 40% of intracellular AAV2 consistently associated 
with lysosomes between 2 hours and 13 hours after infection 
(Supplementary Figure S6).
Nuclear entry of either viral proteins or genetic material, follow-
ing the small vesicle trafficking, is one of the rate-limiting steps in 
most viral infection. Extensive effort has been made to block this 
step in antivirus strategies or to improve the efficiency of this step for 
more efficient gene delivery.15,21–23 Like several DNA viruses,23 AAV2 
has to enter the cell nucleus to complete its life cycle.15,24 However, 
such trafficking kinetics as well as the mechanism through which 
AAV enters nucleus remains unknown due to the lack of a quantita-

























































































Figure 3 Fluorescence properties of single cy5-AAV2 particles within cells. HeLa cells were incubated with Cy5-AAV2 (5,000 vg/cell) and fixed 
and nuclei were stained with 4′,6′-diamidino-2-phenylindole. Stacks of images throughout the cells were taken using a Zeiss710 confocal microscope. 
(a) Representative 3D confocal image of Cy5-AAV2 within cells after being deconvolved and reconstructed (left). Right panel shows the  corresponding 
3D isosurface rendered image. Bar = 5 μm. (b) Histograms of volume (A) and total fluorescence intensity (B) for all Cy5-AAV2 particles within cells 
(n = 5) as calculated by Imaris program. The mean value of total fluorescence intensity was 47,568 ± 13,345.5 a.u. AAV, adeno-associated virus.
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3D tracking of single viral particles to explore the dynamics of AAV2 
nuclear entry in cultured cells.
Experiments were carried out as lysosomal association stud-
ies, and nuclei were stained with DAPI. After 3D deconvolution 
and reconstruction of image stacks, we quantitatively documented 
the kinetics of AAV2 nuclear targeting (Figure 4, Supplementary 
Video S3–S5). We observed that the number of viral particles 
(~200) associated with the cell did not change significantly over the 
time period we observed (Figure 4b-A). On average, 0% and 14% 
of total intracellular viral particles were found in the nucleus at 0 
hour and 2 hours p.i., respectively, and this percentage increased to 
22% at 4 hours, 28% at 8 hours, and 27% at 13 hours (Figure 4b-B). 
With the previous measured mean value of Cy5 TFI (47568 a.u.) 
for a single Cy5-AAV2, the corresponding viral particle numbers 
in the nucleus were 27, 38, 48, and 41 at 2 hours, 4 hours, 8 hours, 
and 13 hours, respectively (data not shown). These results sug-
gest the following dynamics of AAV2 nuclear targeting: (i) Half 
of the nuclear targeting events happened within the first 2 hours 
p.i., with the remainder occurring between 2 and 8 hours p.i. This 
correlates well with the fact that reporter gene (GFP) expression 
can be detected as early as 6–8 hours p.i. (ii) The relative number 
of AAV2 in the nucleus appears to level off at 8 hours p.i., with 
about 30% (48 out of 170) intracellular AAV2 particles on aver-
age located in the nucleus. This result is consistent with an ear-
lier report which found that a similar percentage of AAV genome 
(~30%) ended up in the nucleus.25 These results were summarized 
into an in vitro model (Figure 6a) and quantitatively documented 
in a table (Figure 6c, upper panel). Remarkably, the percent-
age of AAV2 associated with the nuclear membrane (~12%) at 
2 hours p.i. did not change when the viral dosage was increased 
to 25,000 v/cell. However, nuclear entry efficiency at 2 hours p.i. 
with 25,000 vg/cell (~4%) was significantly decreased (three-
fold) compared to that with 5,000 vg/cell (~14%) (Figure 4c,d). 
These results suggest that limited sites for viral entry are avail-
able on the nuclear membrane or limited trafficking routes 
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Figure 4 Kinetics of cy5-AAV2 nuclear targeting. HeLa cells were incubated with Cy5-AAV2 (a,b: 5,000 vg/cell; c,d: 5,000 or 25,000 vg/cell) at 
4 °C for 40 minutes and then transferred to 37 °C incubator. Cells were then fixed at 0, 2, 4, 8, and 13 hours and nuclei were stained with 4′,6′-diamidino-
2-phenylindole. The number of viral particles within cells was calculated using the mean value of Cy5 total fluorescence intensity (47568 a.u.) 
 determined in Figure 3b-B. (a) Representative 3D isosurface images of Cy5-AAV2 within cells at 0 hour and 8 hours postinfection. Viral particles in 
nuclei are highlighted as yellow. Bar = 5 μm. (b) Plots of total number of viral particles (A) and percentage of intranuclear viral particles (B) in each cell. 
(c) Representative 3D isosurface images of cells infected at 5,000 or 25,000 vg/cell at 2 hours postinfection. Viral particles in nuclei are highlighted 
as yellow. Bar = 5 μm. (d) Percentage of intranuclear and nuclear membrane–associated viral particles as shown in c. Cyan diamond represents data 
from individual cells (n = 10–20), red bars represent mean value of each time point, and error bars represent SD. AAV, adeno-associated virus.
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transduction efficiency measured by transgene GFPsc expression 
at 25,000 vg/cell is only about threefold of that at 5,000 vg/cell 
(Supplementary Figure S7).
trafficking kinetics in mouse muscle
The ultimate goal of studying particle trafficking is to elucidate 
the behavior of viral and nonviral vectors in tissues and animals. 
The in vivo setting provides the most applicable information for the 
development of efficient gene-delivery vectors. Current method of 
studying the distribution of viral vectors in vivo using reporter 
gene assays tracks only the virions that successfully transduce 
cells. Given that the vast majority of virions are likely to be futile 
in infection, reporter gene imaging provides a biased understand-
ing of virion distribution that can easily lead to misinterpretation 
of the pharmacology of these agents, resulting in failed develop-
ment of antiviral and therapeutical delivery vectors.4,26 To circum-
vent this problem, we have successfully tracked all AAV particles, 
both infectious and abortive, in mouse muscle over time.
After local injection with Cy5-AAV2 particles, mouse hind 
limb muscle were collected at 0.5, 2, 4 hours and 6 days. Reporter 
gene (GFP) expression spread up to several muscle fibers away from 
the injection site, indicated by Indian ink (arrows in Figure 5a,b), 
and was stronger in those fibers closer to the injection site than 
in the fibers distal from injection site at 6 days p.i. (Figure 5a). 
The immediate question is whether this distribution pattern rep-
resents the spreading of GFP molecules or viral particles across the 
muscle fibers. Our results showed that, in contrast to Indian ink 
remaining local to the site of injection (Figure 5b, upper panel), 
AAV particles migrated from the injection site into the neighbor-
ing fibers (three muscle fibers away from the injection site). We 
observed that numbers of AAV particles in the surrounding fibers 
and in nuclei increased from 0.5 hour to 4 hours (Figure 5b, lower 
panel and Supplementary Video S6,S7). Almost all Cy5-AAV2 
particles were located at the site of injection after 0.5-hour p.i. A 
few viral particles were observed on the side of fibers (sarcoplasm) 
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Figure 5 trafficking of AAV2 in mouse muscle. (a) Site of AAV injection 
is visualized by Indian ink (black spots in upper panel) and is indicated by 
arrows and corresponding reporter gene GFP expression (green) in mus-
cle at 6 days postinjection (lower panel). Bar = 100 μm. (b) Distribution 
of Cy5-AAV2 particles in mouse muscle at 0.5, 2, and 4 hours postin-
jection. Upper panel shows the differential interference contrast (DIC) 
images with the injection site indicated by arrows. Lower panel shows 
the localization of Cy5-AAV2 particles (red) and nuclei (blue). The inserts 
in upper panel are the magnified view of selected regions in lower 
panel (white boxes). Bar = 10 μm. (c) Cy5-AAV2 particles were detected 
inside the muscle fibers at 6 days postinjection. Upper panel shows the 
expression of reporter gene GFP in muscle fibers. Lower panel shows the 
Cy5-AAV2 particles (red) and nuclei (blue). Individual muscle fibers are 
outlined by curved white lines. Arrowheads indicate the viral particles 
inside the fibers and arrows indicate the viral particles along the side of 
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Figure 6 schematic and quantitative documentation of AAV2 traf-
ficking in vitro and in vivo. (a) Model for AAV2 infection in cell culture. 
After binding to the cell surface at 0 hour, AAV2 particles are transported 
via microtubules toward the perinuclear region (typically microtubule 
organization center, MTOC) within the first 8 hours after viral inocu-
lation. Progressive nuclear entry is observed during the first 8 hours 
postinfection, with about 30% of viral particles in the nucleus at 8 hours 
postinfection. (b) Model for AAV2 trafficking mouse muscle shown in 
cross-sectioned view. AAV2 particles traffic from the injection site to 
distal myofibers through the endomysium between those fibers. Some 
AAV particles penetrate the muscle fibers, but only at later time point 
(≥24 hours). To quantitatively document the intramuscular trafficking 
in c (Table 2), four regions (I–IV) were defined from the injection site 
to distal myofibers, and the width of each region is about half of myofi-
ber’s diameter. (c) Quantitative documentation of AAV2 distribution and 
trafficking kinetics in cultured HeLa cells (Table 1) and mouse muscles 
(Table 2). AAV, adeno-associated virus.
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particles appeared on the side of fibers close to (three muscle fibers 
away from) the injection site at 4 hours p.i. Such trafficking kinet-
ics was summarized in an in vivo trafficking model (Figure 6b) 
and quantitatively documented in a table (Figure 6c, lower panel). 
During this time period, viral particles were only observed along 
the side of muscle fibers (sarcoplasm) but not inside the fibers 
prior to 4 hours p.i. (Figure 5b, lower panel) and the number of 
AAV capsids in nucleus was increased over time (Figure 6c). This 
observation suggests that viral particles after intramuscular injec-
tion are likely to spread through the endomysium between muscle 
fibers, rather than by transcytosis. In addition, at 6 days p.i., AAV 
capsids were only observed along and inside the muscle fibers but 
not detectable in most of the nuclei (Figures 5c,6c). This observa-
tion suggested that most AAV genome should be readily released 
quite rapidly in vivo.
dIscussIon
Understanding how nanoparticles travel through the cellular 
structures and how pharmacological reagents can affect viral traf-
ficking is essential for the development of enhanced gene therapy 
vectors (e.g., polymers, adenovirus, and AAV).3 Fluorophore label-
ing of particles has been mainstay in studying the dynamics of 
particle trafficking.10,11 While a fancy research tool, current molec-
ular tracking and 2D imaging analyses have significant limitations 
in studying classical viral trafficking and biodistribution,13,14 in 
which temporal resolution is not the primary interest. For exam-
ple, sampling all intracellular viral particles and quantitatively 
studying their distribution and trafficking kinetics in 3D animal 
cells and tissues has not yet been achieved. Although investigation 
of biodistribution and trafficking kinetics of DNA carrier vectors 
have been attempted previously,12,13 these studies are 2D imaging 
analyses that have limitations in quantitatively characterizing the 
viral behavior in 3D cellular structures. For example, classical 2D 
imaging and analysis can lead to arbitrary results, as the distri-
bution patterns in different focal planes vary along the z-axis of 
confocal images. As a result, neither distribution data gained from 
a specific focal plane nor that simply summed up from all focal 
planes is able to correctly reflect the behavior of virus in cells. 
Recently, Chen et al. studied the trafficking kinetics of plasmid 
carriers by measuring the volume of fluorescence spot generated 
by labeled particles.19 As known, the amount of dye molecules 
(or dye- labeled particles) in a subresolutional region (diameter 
< 150 nm) should be calculated by the amount of emitted photons 
linearly reflected by fluorescence intensity in confocal images20,27 
but not by fluorescence volume, as there is no linear correlation 
between number of dye molecules (or labeled particles) and fluo-
rescence volume (Supplementary Figure S2a). As a result, the 
amount of emitted photons or fluorescence intensity instead of 
fluorescence volume should be used to quantitate dye-labeled 
subresolutional-sized particles (Supplementary Figure S2). The 
method described in this study directly uses fluorescence intensity 
information to quantitatively determine the number and distribu-
tion of nanoscaled particles in three dimensions (Supplementary 
Figure S2, Figures 2d-B,3b-B), which is fundamentally differ-
ent from the volume-based method.19 In addition, restorative 
3D deconvolution was also applied to appropriately counteract 
the image distortions caused by optical systems to increase the 
accuracy of this 3D image analysis (Supplementary Figure S1).20 
In brief, this method has employed multiple strategies includ-
ing isosurface-assisted object-by-object analysis (Figure 1b), 
 intensity-based calculation (Supplementary Figure S2), and 
restorative 3D deconvolution (Supplementary Figure S1) to 
significantly improve the  accuracy of 3D image quantification. 
Compared with previous studies, including the improved pre-
cision of image quantification, this method not only allows one 
to view the particle trafficking from an entire viral population 
(Figures 4,6c) but also, for the first time, allows one to locate each 
individual particle into finer subcellular structures (i.e., inside/
outside nucleus or traversing nucleus, as shown in Figure 1b 
and detailed localization in muscle as shown in Figure 5c). By 
determining the fluorescence parameter for a single Cy5-AAV2 
virion (Figures 2,3), this method also allows one to quantitate 
the absolute number of particles in each cellular structure such 
as nucleus (Figure 4), microtubules, and cell surface (data not 
shown) as well as subresolutional vesicle structures like endo/
lysosomes (Supplementary Figure S6), which have never been 
reported previously. Finally and importantly, this method, for the 
first time, allows one to quantitatively investigate particle biodis-
tribution/trafficking in animal tissues (Figure 5), which have not 
been documented by any of the above method.
Our electron microscopy data demonstrates that almost 
all Cy5-AAV2 virions we used in this study are full particles 
(Supplementary Figure S3a). The labeled virions are shown 
to preserve the capsid integrity as determined by A20 antibody 
binding (Supplementary Figure S3e) and have similar infectiv-
ity as nonlabeled AAV2 (Supplementary Figure S3b,c). These 
labeled virions are also shown to have the normal ability to bind 
heparan sulfate and migrate on microtubules (data not shown). 
Using these Cy5-AAV2 that preserve the same morphology and 
functionality as unlabeled ones, we have generated a body of 
interesting and biologically meaningful results consistent with 
previous reports as well as several novel observations that have 
never been documented previously. For example, we have quan-
titatively demonstrated that the majority of AAV2 are bound to 
the cell surface as single particles even at a high multiplicity of 
infection and the binding of AAV2 can be blocked by incubating 
the virus with heparin or incubating cells with heparanase (data 
not shown), supporting previous reports showing heparan  sulfate 
is the primary receptor for AAV2.5,28 We then demonstrated that 
AAV2 can migrate on microtubules and that disruption of the 
microtubule network impaired the nuclear targeting of AAV2 
(data not shown). The kinetics of AAV2 trafficking in small vesi-
cles like lysosomes was illustrated using this quantitative micros-
copy method (Supplementary Figure S6). In addition, we also 
explored the kinetics of AAV2 nuclear trafficking, one of the most 
important events in AAV infection, by quantitating the number 
and percentage of AAV particles in nuclei over time (Figures 
1b,4,6c). Importantly, we have, for the first time, quantitatively 
characterized the trafficking behavior of AAV2 in mouse muscle 
tissue (Figures 5b,6c), providing rationale for the pattern of viral 
transgene expression in vivo. We will discuss some of these find-
ings in detail in the following text.
Nuclear entry is regarded as the most critical and rate- limiting 
step for the life cycle of most DNA viruses (e.g., adenovirus, 
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herpesvirus, and parvovirus).23,29 Blocking the nuclear entry is 
an alternative way to block viral replication,21,23 and on the other 
hand, facilitating the nuclear entry of viruses has been a prom-
ising strategy to improve viral vectors for gene delivery.15,22,30,31 
Several groups have suggested that AAV entered nucleus as intact 
virions.5,15,24 For example, the Kleinschmidt group demonstrated 
that intact AAV2 particles enter the nucleus, as nuclear injection 
of the A20 antibody can block AAV2 infection and disassembled 
AAV particles are not detected by B1 antibody until 20 hours after 
infection.24 Our group showed that AAV enters the nucleus as 
intact virions and nuclear virions could be extracted and used to 
reinfect new cells.15 These most recent studies suggest that AAV 
enters nucleus as intact virions and then uncoats there. However, 
the kinetics of AAV nuclear targeting has not been precisely docu-
mented and the exact route/site for viral nuclear entry is highly 
controversial. The method described herein was used to quanti-
tatively investigate the viral nuclear entry step. Our microscopy 
analysis of AAV documented the kinetics of nuclear entry over 
13 hours p.i. (Figures 4,6c), summarized in the in vitro model 
(Figure 6a). The result showing that about 30% of bound AAV2 
particles entered nucleus, together with the observation showing 
that only about 4%–5% (~200 out of 5,000 virions/cell) of particles 
in the medium attached to cell surface, suggests that only 1%–2% 
of AAV2 virions will eventually enter the nucleus and express. 
Such binding efficiency was verified by quantitative polymerized 
chain reaction (data not shown) and also reported by other stud-
ies for other AAV serotypes.32 This low binding efficiency is due to 
the nature of biochemical reaction between ligands (AAV2) and 
receptors (heparan sulfate on cell surface) rather than the qual-
ity of AAV prep because the unbound particles remaining in the 
medium can be transferred to successfully infect new cells as well. 
These results propose the existence of a noninfectious traffick-
ing pathway as another reason for the high particle-to-pfu phe-
nomena in AAV infection in addition to the defective particles in 
AAV preparations. We also noticed a wide variation in the num-
ber of nuclear particles per cell at every time point (Figure 4b). 
This supports a highly heterogeneous susceptibility of each cell 
to AAV2 infection and explains the variation of AAV2 transgene 
GFP expression among individual cells (unpublished data). 
As a result, by quantitating the number of virions in a single cell as 
accessible by this method, one will be able to correlate the number 
of viral particles in a cell with the amount of transgene  expression 
to address questions like how many virions are needed to express a 
certain amount of transgene. Typically, one will be able to observe 
the expression of double-stranded GFP transgene in vitro at about 
6–8 hours after infection. Given the several hours required for 
the maturation of a GFP molecule to give fluorescence,33 such 
observation indicates that viral particle should enter nucleus and 
release genome within couple of hours p.i. The kinetics of AAV 
nuclear trafficking revealed in this study clearly demonstrated the 
early AAV2 nuclear entry events within 2 hours p.i. (Figure 4b), 
which provides a molecular rational for such a gene expression 
profile. In dose response studies, the number of virions in the 
nucleus does not increase linearly with the number of nuclear 
membrane– associated virions at 2 hours p.i. (Figure 4d). This 
result suggests that there may be limited sites/routes for AAV2 
nuclear entry through the nuclear membrane and provides a sound 
explanation for the observation that the fold increase in virion 
dosage does not translate to equivalent fold increase in transduc-
tion (Supplementary Figure S7). Experiments to confirm this 
hypothesis are ongoing. With such scenario, this method enables 
one to quantitate the effects of pharmacological drugs and AAV 
variants on the nuclear transportation of AAV particles to facili-
tate the direction towards improving this vector’s performance.
Similar to the documentation of nuclear entry dynamics, 
the kinetics of viral trafficking through other cellular structures 
(i.e., small vesicles, cell surface, microtubules) can also be docu-
mented with this method (Supplementary Figure S4, and data 
not shown). The spatial-temporal distribution of all viral particles 
within the host cells throughout the entire trafficking pathway 
can be determined by integrating all the information regarding 
the kinetics of virions in various cellular structures. It is noted 
that about 1:100 rAAV2 particles are infectious consistent with a 
recent report,16 suggesting that only 1 out of 100 viral particles in 
culture medium will successfully infect a cell in the culture dish. 
Our study shows that only about 5% of rAAV2 in the medium 
will attach to the cell surface for internalization (as suggested by 
Figure 4b). Our heparin competition and heparanase treatment 
studies demonstrate that all particles tracked in these experiments 
were 100% positive for first step in infectious pathway (i.e., viral 
binding), making the above observations relevant irrespective of 
the particle-to-infectious-unit ratio (data not shown).
Understanding the distribution of viral and nonviral vectors 
in vivo is extremely valuable to advance current drug/DNA deliv-
ery strategies. In this study, we have successfully applied our quan-
titative 3D microscopy method to study the distribution of AAV2 
particles in animal tissues. We and other groups have observed the 
limited spreading of AAV2 transduction around the needle track 
as indicated by the expression pattern of various reporter genes 
(Figure 5a).34–36 However, there is no direct evidence on AAV2 
trafficking that provides the molecular rationale for such transgene 
expression profiles in vivo. To address this question, we used the 
quantitative microscopy method to directly quantitate the distri-
bution of AAV2 particles in mouse muscle over time. Our results 
for the first time showed that the AAV2 particles were localized at 
the injection site during the first 30 minutes and then uniformly 
spread through tissues up to three muscle fibers away from the 
injection site over 4 hours (Figure 5b). This result is significant 
in that it allows one to correlate viral spread with expression and 
should provide insight into vector tropism when studying capsid 
variants specific for muscle or various tissues such as brain and 
eye.34,35,37–39 Another important question is how the viruses traf-
fic to the cells distal from the injection site.34,35,37–40 Transcytosis 
has been proposed as a mechanism for the spreading of various 
viruses, including HIV, poliovirus, and AAV, and most of these 
studies involved epithelial cell barriers using in vitro transwell cell 
culture.40–42 However, little information is available regarding the 
mechanism of trafficking for AAV particles in vivo. Our studies 
using this quantitative 3D microscopy method show that almost all 
viral particles localized to the boundary of the muscle fibers (sar-
coplasm) but not inside the fibers when trafficking to the distant 
fibers (Figure 5b). This observation strongly suggests that most 
AAV2 particles traffic through the endomysium between mus-
cle fibers instead of traversing through myofibers. These virions 
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between muscle fibers, we believe, are infectious as indicated by 
the transgene expression in these muscle cells (Figure 5a). It is also 
noteworthy that the trafficking kinetics showing virions in muscle 
nuclei at 30 minutes to 4hours (Figure 5b) combined with the 
absence of AAV2 in nuclei at 6 days p.i. (Figure 5c) suggests that 
nuclear AAV2 vectors release their genomes quite rapidly. Previous 
reports demonstrated that the expression of AAV2 transgenes in 
muscle did not reach the peak until around 5 weeks p.i.34,43 These 
studies in combination may support that, after uncoating, AAV2 
transduction may be impacted by other cellular factors such as the 
rate-limiting step of second strand synthesis.44–46 Additionally, at 
6 days after injection, AAV2 particles were also detected inside of 
the muscle fibers/cells (Figure 5c). This observation supports a 
hypothesis that, unlike in cultured cells, viral particles in vivo can 
persist in myofibers potentially providing a temporal reservoir of 
virus. And these virions may traffic to the nucleus and contrib-
ute to viral transduction at later times (over 2 weeks), which also 
could be an explanation to the observed AAV transduction profile 
in muscle.34,43
This quantitative 3D distribution microscopy approach 
 presented here was originally designed to quantitatively exam-
ine how pharmacological reagents and viral genetic variants 
impact the trafficking kinetics and biodistribution of viral vectors. 
With this approach, we have generated a panel of very interest-
ing and biologically meaningful results consistent with previous 
reports as well as several novel observations that have not been 
 previously documented. These findings both support the current 
 working knowledge of AAV biology and provide a better mech-
anistic insight into the behavior of this viral vector in vitro and 
in vivo. It will be of particular interest to quantitatively compare 
the  trafficking behavior of various AAV serotypes and chimeric 
vectors, as well as mutant capsids defective/enhanced in viral traf-
ficking. Data from such studies should provide guidance for the 
rational design of optimal gene therapy vectors. Therefore, such 
an ability to quantitate the distribution and trafficking kinetics of 
nanoparticles (Figure 6c) should facilitate a quantitative evalua-
tion of the effects of pharmacological reagents and vector variants 
on the delivery performance of these particles in cultured cells as 
well as animal tissues. Finally, in combination with pharmacologi-
cal tools and live cell imaging, this 3D quantitative distribution 
microscopy approach will provide a comprehensive and powerful 
method to understand the physiological life cycle of gene-delivery 
vectors as well as the intracellular behavior of other nanoparticles 
in vitro and in vivo.
MAterIAls And Methods
Production and purification of viruses. Virus was produced in HEK-
293 cells as previously described.47 Briefly, using polyethylenimine (lin-
ear molecular weight, ~25,000), cells were triple transfected with pXR2, 
the pXX680 helper plasmid, and pTR-CMV-GFP containing the GFP 
reporter transgene flanked by inverted terminal repeats. At 60 hours 
 posttransfection, cells were harvested and nuclei were isolated as previ-
ously described.47 The nuclear pellet from 10 plates was resuspended in 
10 ml phosphate-buffered saline (PBS) with 0.5% deoxycholate (DOC) 
and then sonicated for 1 minute. This suspension was incubated at 37 °C 
for 45 minutes in the presence of 100 μg/ml DNase. Virus suspension was 
subjected to one round of cesium chloride (CsCl) step gradient density 
(1.3 g/cm3 and 1.5 g/cm3) fractionation. The viral fraction that resided in 
the interface between the two gradients was collected and subjected to 
another round of fractionation using CsCl continuous gradient density. 
Fractions that contained peak virus titers as determined by both slot dot 
blots and SDS-PAGE electrophoresis were dialyzed against 1× PBS supple-
mented with 5% sorbitol. Viral titers were determined by both dot blot47 
and qPCR. The infectivity of AAV is determined to about 1 transduction 
unit per 100 particles.
Cy5 labeling of viral particles. AAV2 was covalently labeled with fluo-
rophores as described.48 AAV2 labeling followed essentially the same 
protocol with slight modification. Briefly, purified AAV2 was incu-
bated for 1 hour at 4 °C in PBS with a tenfold molar excess of Cy5 mono 
N-Hydroxysuccinimide (NHS) esters (GE Healthcare, Piscataway, NJ) 
over the capsid protein units. Labeled viruses were separated from the free 
dyes by dialysis against PBS containing 5% sorbitol and stored at −80 °C 
as small aliquots. The degree of labeling (DOL) was determined by spec-
tophotometry using DOL = Amax / ([virus] × Edye), with Amax = absorbance 
of dye at absorbance maximum, [virus] = virus concentration, and Edye = 
extinction coefficient of the dye at its absorbance maximum. Please refer to 
the manufacturer’s instructions for further details. Labeled viral titers were 
determined by both dot blot47 and qPCR.
Vector administration and animal studies. Housing and handling of 
BALB/c mice used in the current study were carried out in compliance 
with the National Institutes of Health guidelines and approved by the 
IACUC at the University of North Carolina–Chapel Hill. Recombinant 
AAV2 vectors packaging GFP transgenes were administered through the 
intramuscular (2 × 109 vg into the hind limb) in a volume of 20 μl PBS. At 
0.5, 2, 4 hours and 6 days after intramuscular injection, animals received an 
overdose of pentobarbital (100 mg/kg intraperitoneally) and were perfused 
transcardially with ice-cold 100 mmol/l sodium PBS (pH 7.4), followed by 
4% paraformaldehyde in PBS (pH 7.4). After muscle was postfixed for 24 
hours at 4 °C in paraformaldehyde/PBS,49 15 μm cross-sections were cut 
using a cryosection microtome. Then the slides were directly sealed with 
mounting medium (Prolong Antifade Gold with DAPI; Molecular Probes, 
Eugene, OR).
Immunofluorescence. Similar to what we have previously described,15 
HeLa cells (3 × 104  per well) were plated on 12-mm glass coverslips 
at 24 hours before infection. Next day, after incubation in Dulbecco’s 
Modified Eagle Medium containing 20 mmol/l 4-(2-hydroxyethyl)-1-
 piperazineethanesulfonic acid at 4 °C for 5 minutes, cells were incubated 
with Cy5-labeled virions (5,000 or 25,000 vg/cell) at 4 °C for another 40 
minutes. Cells were washed three times with PBS to remove unbound 
viruses and transferred to 37 °C incubator (regarded as 0 hour p.i.). At 
the indicated time points, cells were washed with PBS and then fixed with 
4% paraformaldehyde for 15 minutes at room temperature (RT). The cells 
were then permeabilized with 0.2% Triton X-100 in PBS for 5 minutes at 
room temperature. Following four washes with PBS, the permeabilized 
cells were blocked with immunofluorescence buffer (5% normal goat 
serum in PBS containing 0.05% Tween-20) for 1 hour at room tempera-
ture. The cells were incubated with primary antibody to detect Lamp1 
(monoclonal from Santa Cruz Biotechnology, Santa Cruz, CA) diluted in 
50% immunofluorescence buffer for overnight at 4 °C. The cells were then 
incubated in secondary  antibody, diluted 1:2,000 in 50% immunofluores-
cence buffer (anti-mouse  Alexa-Fluor 488 (Molecular Probes)), for 1 hour 
at room temperature. After six washes with PBS, coverslips were mounted 
cell side down on glass slides with mounting medium (Prolong Antifade 
Gold with DAPI; Molecular Probes).
3D confocal fluorescence microscopy and 3D blind deconvolution. The 
labeled HeLa cells were examined by use of a Zeiss LSM710 laser scanning 
confocal microscope equipped with a Zeiss Plan-Apochromat 63×/NA 
1.40 oil objective. The confocal pinhole aperture was set to the diameter 
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of the first Airy disk. Stacks of 20–30 focal planes were captured at 0.31 μm 
z- intervals through the depth of the cell. 3D images of the cells were 
 reconstructed by using the image stacks. The Nyquist theorem, which uti-
lizes the limitation of the microscope optics (full width at half maximum) to 
dictate adequate sampling, was used to determine that pixel dimensions of 
0.13 × 0.13 × 0.31 μm (X, Y, Z) were required to properly sample the data.
Deconvolution was performed by AutoDeblur software (Media 
Cybernetics, Bethesda, MD), using iterative and constrained algorithms. 
The procedure started with a theoretical PSF derived from the actual 
setting of Zeiss710 confocal microscope. To generate the theoretical 
PSF, AutoDeblur took the following factors into consideration: NA of 
the microscope objective, refractive index of the medium, excitation 
wavelength, emission wavelength, confocal pinhole radius, pixel size, 
z-axis interval, microscope type (i.e., wide field, confocal), and number 
of excitation photons. A new adjusted adaptive PSF derived from the 
previous deconvolution round was used to generate next adaptive PSF 
that fits the real imaging data better than the previous one (termed as 
one iteration or deconvolution round20). The number of iterations may 
serve as a regularization factor. In general, the remaining restoration 
error decreases with an increasing number of iterations. At the same 
time, the error due to noise amplification increases. The procedure should 
be stopped at an iteration number in which the sum of both errors is 
minimal.50 To determine the optimal number of iteration, intracellular 
Cy5-AAV2 particles were deconvolved up to 50 rounds and the resulting 
images were saved every five rounds. The resulting images from 10 
deconvolution rounds (number of iteration) displayed the highest signal-
to-noise ratio, best spatial resolution, and most closely resemble the 
fluorescence signal from a point light source (Supplementary Figure 
S1b). This iteration number (10 rounds) was then used to deconvolve all 
the confocal images in this paper.
Computer-assisted 3D visualization and analysis. All deconvolved 
image stacks was processed using IMARIS software package (Bitplane AG, 
Zurich, Switzerland) for visualization and quantification purpose. Briefly, 
a deconvolved image stack was reconstructed using a volume rendering 
module and smoothened by a 3D-median filter. Subsequently, an isosur-
face rendering  module was applied through thresholding by the fluores-
cence intensity that is slightly higher than background. For Cy5-AAV2, 
the isosurface rendering was thresholded at the fluorescence intensity of 
1,000 a.u. (the upper boundary of background). ForAF488-Lamp1, the 
fluorescence intensity of 530 a.u. was used. For DAPI, isosurface render-
ing was thresholded at the fluorescence intensity of 2,500 a.u. The param-
eters (volume, MFI, TFI) for these isosurface-coated Cy5-AAV2 objects 
were extracted from the IMARIS program and analyzed as described in 
Results section. The localization of Cy5-AAV2 in nucleus or lysosomes 
was analyzed as described in Results section. Aberrations caused by refrac-
tive index mismatch results in a suboptimal z resolution. Full width at half 
maximum changes of the PSFs of the two channels (DAPI and Cy5) dif-
fered one voxel (0.13 × 0.13 × 0.31 μm3) in XY- and Z-directions, while no 
significant changes were observed between AF488 and Cy5. The channel 
registration difference between DAPI and Cy5 was fixed by adjusting the 
DAPI channel using channel shift module in IMARIS to avoid potential 
false-positive localization results.
Atomic force microscopy. After imaging with confocal microscope, the 
coverslips were removed from glass slides and gently rinsed with PBS. The 
coverslips were quickly rinsed in ddH2O, blotted dry, and then slightly 
dried under a stream of nitrogen. The images were captured in air with 
a Nanoscope IIIa (Digital Instruments, Santa Barbara, CA) microscope 
in tapping mode. Pointprobe tapping mode silicon probes (Molecular 
Imaging, Tempe, AZ) with spring constants of ~50 N/m and resonance 
frequencies ~170 kHz were used for all imaging. The images were collected 
at a speed of 4 Hz, a size of 4 μm × 4 μm, and a resolution of 512 × 512 
pixels.
Electron microscopy. Purified and dialyzed virus particles in 1× PBS were 
pipetted onto a glow-discharged copper grid. The grid was washed twice 
with water and then stained with 2% uranyl acetate. Electron microscopy 
images were taken with a LEO EM 910 transmission electron microscope 
at various magnifications.
suPPleMentArY MAterIAl
Figure S1. Theoretical point spread function of confocal images and 
optimization of 3D deconvolution.
Figure S2. Total fluorescence intensity is proportional to the amount 
of dyes and dye-labeled beads.
Figure S3. Evaluation of AAV2 morphology and infectivity after 
chemical conjugation with Cy5.
Figure S4. Visualization of Cy5-AAV2 particles within cells by fluores-
cence microscopy.
Figure S5. Mean fluorescence intensity of single Cy5-AAV2 on cover-
slips and in cellular environment.
Figure S6. Association of Cy5-AAV2 with the lysosomes.
Figure S7.The level of transgene GFPsc expression at two different 
viral dosages.
Video S1. Isosurface rendering of Cy5-AAV2 fluorescence signal.
Video S2. Isosurface rendering–assisted 3D localization of Cy5-AAV2 
particles in cell nucleus at 6 hours postinfection.
Video S3. Isosurface rendering reveals the localization of Cy5-AAV2 
particles in HeLa cells at 0 hour after binding.
Video S4. Isosurface rendering reveals the localization of Cy5-AAV2 
particles in HeLa cells at 2 hours after binding.
Video S5. Isosurface rendering reveals the localization of Cy5-AAV2 
particles in HeLa cells at 8 hours after binding.
Video S6. Isosurface rendering reveals the spreading of Cy5-AAV2 par-
ticles in mouse muscle tissue at 2 hours after intramuscular injection.
Video S7. Isosurface rendering reveals the spreading of Cy5-AAV2 par-
ticles in mouse muscle tissue at 4 hours after intramuscular injection.
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